STIFEL 2026 HEALTHCARE CONFERENCE - DEFINIUM THERAPEUTICS INC

Explicit Guidance:

• None. Management explicitly declined to provide specific financial guidance (revenue, earnings, capex, etc.) or timeline updates until fully aligned with the FDA, stating they will not issue public guidance on engagement until "absolutely certain" regarding regulatory standing.

Business-Segment Outlook:

• DT120 (LSD for GAD/MDD): Submit an NDA to the FDA in the "first half of next year" (FY2026) covering both Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
• DT120 Development Strategy: If the FDA requires a second MDD pivotal study, the company will proceed with a submission for GAD alone first using existing data, while simultaneously running a second MDD Phase 3 study (now enrolling) to provide reassurance or support a combined label later.
• DT402 (R-DMAD for Autism Spectrum Disorder): Following a positive Early Signals of Efficacy (ESE) readout in a 5-patient open-label cohort, development will continue. The target population for near-term studies remains patients with "preserved language skills," with plans to eventually expand to those with more profound deficits.
• PTSD Program: Initiation of a new Phase 3 study for DT120 in PTSD is scheduled to begin "next year" (FY2026).
• Headcount & Operations: Current workforce is 194 employees with an aggressive hiring trajectory of adding "10 a week," indicating significant operational expansion and increased near-term opex.

Market and Competitive Outlook:

• Competitive Positioning: Differentiation strategy positions DT120 as a unique "classic psychedelic" (5-HT2B binding) compared to competitors' products, anticipating FDA recognition of distinct regulatory pathways based on individual drug characteristics rather than a generic "psychedelic" label.
• Labeling Expectations: Anticipate a label reflecting a non-prophylactic, "as-needed" redosing paradigm (treating only when symptoms return) rather than daily maintenance dosing, distinguishing it from SRIs, Spravato, and competitor products.
• REMS Precedent: Management expects to "front-run" regulatory hurdles regarding REMS (Risk Evaluation and Mitigation Strategies) and redosing rules compared to competitors (Comp360, USONA), citing extensive data collection on observation periods and safety in their own studies.

Macro / Industry Outlook:

• Regulatory Environment: Views the current FDA as "enthusiastic" to regulate psychedelics with a shared goal of safe and efficious patient access, contrasting this with the perceived "slow-down" stance of five years ago.
• Societal Drivers: Notes a shift in cultural and political consciousness regarding mental health, specifically citing "one veteran a day dying of mental illness" as a driver for increased regulatory receptiveness.
• Regulatory Capacity: Acknowledges the FDA is currently "understaffed" due to recent administration changes but expects a framework focused on patient benefit rather than risk avoidance.

Strategic Initiatives:

• NDA Submission: Execution of NDA filings for DT120 in H1 of next year.
• Clinical Trials Expansion:
  • Running "Part Bs" (9-month open-label extension) of GAD/MDD studies to gather naturalistic safety/efficacy data (up to 4 additional doses).
  • Launching a second MDD Phase 3 study with a 50mcg perceptible control arm to confound participants and validate efficacy signals against placebo effects.
  • Initiation of a Phase 3 study for PTSD in FY2026.
  • Designing future Phase 3 studies for DT402 (ASD) with plans to publish concepts soon.
• R&D Focus: Intentional design of all studies to address specific regulatory endpoints (REMS, redosing, observation periods) to ensure favorable labeling outcomes.

Risks and Headwinds to Outlook:

• Regulatory Delays: Potential FDA requests for a second MDD study could delay a combined GAD/MDD submission, necessitating a staged GAD-only approach.
• Workforce Scaling: The rate of hiring ("10 a week") is described as "alarming," suggesting potential operational complexity or resource strain risks.
• Safety Signals: Management acknowledges theoretical safety concerns for DT402 (DT402) regarding valvulopathy (cardiac toxicity) historically associated with racemic MDMA, though they believe the R-enantiomer reduces this risk.
• Study Design Challenges: Concerns regarding the "perceptibility" of lower control doses in the second MDD study to prevent placebo confounding, though this was mitigated by study design.
• Competitor Outcomes: While management believes their data is robust, the final labeling of competitors (Comp360, USONA) regarding REMS and redosing remains a variable, though management asserts their data is superior due to prior intentional study design.

Management Tone on the Future:

• Confidence: High confidence in the strength of DT120 data ("extraordinarily reassuring," "data in the bag") and the ability to navigate the FDA process through early and continuous engagement.
• Caution on Disclosure: Deliberately cautious regarding public timelines; management refuses to speculate on FDA alignment until "entirely aligned" to avoid political or regulatory friction.
• Strategic Certainty: Strong conviction that the company's specific developmental choices (study designs, control arms, safety data collection) provide a clear path to approval distinct from competitors.
• Optimism: Positive outlook on the changing regulatory and cultural landscape in psychiatry, viewing the FDA's current stance as an opportunity rather than a barrier.

Miscellaneous:

• DT402 (ASD) Mechanism: Distinct from classic psychedelics; R-DMAD functions via social awareness and intention (analogous to psychostimulants in ADHD) rather than perceptual changes, with effects observed within a single 6-hour evaluation day.
• Commercial Model Vision: DT402 envisions an "as-needed" or daily dosing model similar to psychostimulants to enable behavioral interventions, rather than a single-dose curative model like DT120.